Lapatinib as a Dual Tyrosine Kinase Inhibitor Unexpectedly Activates Akt in MDA-MB-231 Triple-Negative Breast Cancer Cells

Author(s): Parham Jabbarzadeh Kaboli*, King-Hwa Ling

Journal Name: Letters in Drug Design & Discovery

Volume 17 , Issue 8 , 2020

Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

Background: MDA-MB-231 is a Triple-Negative Breast Cancer (TNBC) cell line, which is resistant to tyrosine kinase inhibitors, such as lapatinib. Lapatinib is well-recognized as an anti- EGFR and anti-Her2 compound. Here, we report one of the possible explanations for lapatinibresistance in TNBC cells, the most incurable type of breast cancer.

Methods: Using western blotting, we have observed that lapatinib-treated cells enhanced activation of Akt, an oncogenic protein activated at downstream of EGFR signaling.

Results: Anti-EGFR activity of Lapatinib would be counteracted with sustained activation of Akt. We found lapatinib-resistance in TNBC can be managed by administering Akt inhibitors. Further, lapatinib enhanced PI3K/Akt signaling is an alternative pathway to ensure the viability of MDAMB- 231 cells. There might also be unknown targets for lapatinib, which needs further investigation.

Conclusion: This observation opens up a new discussion on overcoming resistance to tyrosine kinase inhibitors, a key challenge in treating TNBC.

Keywords: Breast Cancer, TNBC, Lapatinib, Akt, Resistance, EGFR.

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 17
ISSUE: 8
Year: 2020
Page: [1060 - 1063]
Pages: 4
DOI: 10.2174/1570180817666200212125658

Article Metrics

PDF: 12